Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
12 Months Ended
Dec. 31, 2022
Apr. 15, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Interpace Biosciences, Inc. (“Interpace,” the “Company,” “we”, “us” or “our”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was originally filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023 (the “Original Filing”).    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-24249    
Entity Registrant Name Interpace Biosciences, Inc.    
Entity Central Index Key 0001054102    
Entity Tax Identification Number 22-2919486    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One Morris Corporate Center 1    
Entity Address, Address Line Two Building C    
Entity Address, Address Line Three 300 Interpace Parkway    
Entity Address, City or Town Parsippany    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07054    
City Area Code (855)    
Local Phone Number 776-6419    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 11,565,729
Entity Common Stock, Shares Outstanding   4,311,414  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 274    
Auditor Name EisnerAmper, LLP    
Auditor Location Woodbridge, New Jersey